title: End-stage renal disease in autosomal dominant polycystic kidney disease: a comparison of dialysis-related utilization and costs with other chronic kidney diseases.
abstract: BACKGROUND
  Autosomal dominant polycystic kidney disease (ADPKD) is the leading inheritable cause of end-stage renal disease (ESRD) and one of the leading causes of ESRD overall. ADPKD patients differ from the overall dialysis population; however, there is little published data regarding health care costs for ADPKD patients on dialysis.
  
  
  METHODS
  This retrospective observational cohort study was designed to quantify health care utilization and costs for ADPKD patients with ESRD who received initial services at a single large dialysis organization between January 1, 2007 and December 31, 2009. Parallel results and baseline patient characteristics for control patients with ESRD etiologies other than ADPKD were performed for reference. Dialysis-related utilization and health care costs for patients with ADPKD in ESRD overall and during time horizons that correspond to Medicare-eligibility benchmarks were analyzed. Baseline patient characteristics were described for all patients and included demographics, comorbid illnesses, and clinical characteristics. Dialysis-related utilization, hospitalization rates, and health care costs were considered longitudinally.
  
  
  RESULTS
  Total health care costs for ADPKD patients were high at US$51,048 per patient-year based on the overall analysis. Total health care costs were lower for ADPKD patients than for control patients on dialysis. Patients with ADPKD were generally younger, had a lower Charlson Comorbidity Index, and had lower rates of comorbid conditions, which may have contributed to the lower overall costs seen for patients with ADPKD.
  
  
  CONCLUSIONS
  Health care resource utilization and costs for patients with ADPKD in ESRD requiring dialysis were high, and therapeutic interventions that can prevent or delay the progression to ESRD may increase dialysis-free life for patients with ADPKD.
authors.affiliation: DaVita Clinical Research, Minneapolis, MN, USA.
authors.forename: Steven M
authors.initials: SM
authors.lastname: Brunelli
authors.affiliation: University of North Carolina, Charlotte, NC, USA ; Otsuka America Pharmaceutical, Inc., Princeton, NJ, USA.
authors.forename: Christopher M
authors.initials: CM
authors.lastname: Blanchette
authors.affiliation: DaVita Clinical Research, Minneapolis, MN, USA.
authors.forename: Ami J
authors.initials: AJ
authors.lastname: Claxton
authors.affiliation: University of North Carolina, Charlotte, NC, USA.
authors.forename: Debosree
authors.initials: D
authors.lastname: Roy
authors.affiliation: Otsuka America Pharmaceutical, Inc., Princeton, NJ, USA.
authors.forename: Sandro
authors.initials: S
authors.lastname: Rossetti
authors.affiliation: Otsuka America Pharmaceutical, Inc., Princeton, NJ, USA.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Gutierrez
keywords: ADPKD; chronic kidney disease; dialysis; health care costs